| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.2 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |